Effects of Neutralizing Antibody Production on AAV-PHP.B-Mediated Transduction of the Mouse Central Nervous System
- 114 Downloads
Adeno-associated virus (AAV)-PHP.B, a capsid variant of AAV serotype 9, is highly permeable to the blood-brain barrier. A major obstacle to the systemic use of AAV-PHP.B is the generation of neutralizing antibodies (NAbs); however, temporal profiles of NAb production after exposure to AAV-PHP.B, and the influence on later AAV-PHP.B administration, remains unknown. To address these, AAV-PHP.Bs expressing either GFP or mCherry by neuron-specific or astrocyte-specific promoters were intravenously administered to mice at various intervals, and brain expression was examined. Injection of two AAV-PHP.Bs, separated temporally, showed that as little as a 1-day interval between injections resulted in a significant decrease in expression of the second transgene, with a complete loss of expression after 7 days, paralleling an increase in serum NAb titers. Brain parenchymal injection was explored to circumvent the presence of NAbs. Mice systemically pre-treated with an AAV-PHP.B were injected intra-cerebrally with an AAV-PHP.B expressing GFP. After 2 weeks, marked GFP expression in the cerebellum was evident, showing that pre-existing NAbs did not affect the AAV-PHP.B directly injected into the brain. In contrast, reversing the injection order, i.e., cerebellar injection followed by systemic injection, completely eliminated expression of the second transgene. We confirmed that intra-cerebellar injection produced NAbs in the serum, but not in the cerebrospinal fluid (CSF). Our results indicate that the preclusion of brain transduction by a second AAV-PHP.B administration begins from the first day following systemic injection and is established within 1 week. Serum NAbs can be avoided by directly injecting AAV-PHP.Bs into brain tissue.
KeywordsAdeno-associated virus AAV-PHP.B Cell type-specific promoter ELISA Neutralizing antibody
We thank Asako Ohnishi and Junko Sugiyama for the viral vector production and the maintenance of mice.
YS designed and performed the experiments, analyzed the data, and drafted the manuscript. AK designed the experiments and contributed to production of AAV vectors. KN (ELISA), YM (experiments using rats), and HY (immunohistochemistry) performed the experiments. JS and KH supervised the ELISA experiment. HH designed the experiments and wrote the manuscript.
This research was supported by the program for Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) from Japan Agency for Medical Research and Development, AMED, under the Grant Number JP17dm0207057h0001 (to H. Hirai), and partially supported by JSPS KAKENHI Grant Number 15K18330 (to A. Konno) and 17K14929 (to Y. Matsuzaki).
Compliance with Ethical Standards
The authors declare that they have no competing interests.
- 6.Huda F, Konno A, Matsuzaki Y, Goenawan H, Miyake K, Shimada T, Hirai H (2014) Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model. Mol Ther Methods Clin Dev Article number: 14032. https://doi.org/10.1038/mtm.2014.32 CrossRefGoogle Scholar
- 8.Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L, Chan CM, McCrate M et al (2011) Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 19(11):1971–1980. https://doi.org/10.1038/mt.2011.157 CrossRefGoogle Scholar
- 9.Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19(6):1058–1069. https://doi.org/10.1038/mt.2011.72 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Matsuzaki Y, Konno A, Mochizuki R, Shinohara Y, Nitta K, Okada Y, Hirai H (2018) Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci Lett 665:182–188. https://doi.org/10.1016/j.neulet.2017.11.049 CrossRefPubMedGoogle Scholar
- 21.Sehara Y, Fujimoto KI, Ikeguchi K, Katakai Y, Ono F, Takino N, Ito M, Ozawa K et al (2017) Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson’s disease. Human gene therapy Clinical development 28(2):74–79. https://doi.org/10.1089/humc.2017.010 CrossRefGoogle Scholar